ArticleNature medicine2021
Caution at psychiatry's psychedelic frontier.
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Magnitude of response in treatment and control groups within psychedelic trials for psychiatric disorders: A meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.Psychopharmacology · 2024Pooled it
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Pooled it
- Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial.Journal of vision · 2024Trial
- Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.EClinicalMedicine · 2025Review
- Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.CNS drugs · 2025Review
- The Induction of Dissociative States: A Meta-Analysis.Biological psychiatry global open science · 2025Article
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.Pharmacology research & perspectives · 2025Review
- Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.Annual review of psychology · 2025Review
- If psychedelics heal, how do they do it?Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.Current neuropharmacology · 2024Review
- Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- "On Suggestion" by John Bostock, 1923: A comparison with twenty-first century understandings of the placebo effect.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2023Article
- Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials.Psychological medicine · 2023Review
- Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.BJPsych open · 2023Article
- Article
- Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study.Frontiers in psychiatry · 2023Article
- Psilocybin for Depression: From Credibility to Feasibility, What's Missing?Pharmaceuticals (Basel, Switzerland) · 2022Article
- Validation of a new instrument for assessing attitudes on psychedelics in the general population.Scientific reports · 2022Article
- MDMA-Assisted Psychotherapy for Borderline Personality Disorder.Focus (American Psychiatric Publishing) · 2022Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34635858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.